JCR Pharmaceuticals Co (TYO:4552) has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for JR-441, an investigational drug for treating mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A), according to a Wednesday filing on the Tokyo Stock Exchange.
JR-441, developed using JCR's J-Brain Cargo technology, is a blood-brain barrier-penetrating form of recombinant heparan N-sulfatase.
The drug has also received ODDs from the European Commission and the US FDA. It is currently in clinical trials in Germany and Japan. MPS IIIA is a rare, debilitating condition with no approved treatment in Japan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.